Phathom Pharmaceuticals, Inc. (PHAT): Total Liabilities
$697.32M
As of 2025-12-31
$671.35M
As of 2026-06-30
+42.8%
3-year compound annual growth
+47.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $697.32M | +10.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $631.90M | +29.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $486.60M | +103.1% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $239.62M | +104.3% | 2024-06-14, Balance as of period end |
| 2021-12-31 | $117.28M | +16.3% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $100.84M | +245.1% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $29.22M | n/m | 2021-03-30, Balance as of period end |
| 2018-12-31 | $2.19M | n/a | 2020-03-19, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $697.32M | +10.4% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $262.35M | -13.0% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $465.08M | +6.5% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $28.52M | -23.6% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $65.98M | +55.1% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $397.87M | -7.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $283.19M | +87.6% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare PHAT, CYRX, SNDX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗